Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Sr. VP & Chief Medical Officer | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,982 |
Ending reported balance
After 2022-04-04 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2022-04-01 · Exercise / conversion · Acquired 16,000 · Balance 50,982 Row 2 · 2022-04-01 · Exercise / conversion · Acquired 31,664 · Balance 82,646 Row 3 · 2022-04-01 · Exercise / conversion · Acquired 2,895 · Balance 85,541 Row 4 · 2022-04-01 · Sale · Disposed 8,299 · Balance 77,242 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive. Row 5 · 2022-04-01 · Sale · Disposed 42,260 · Balance 34,982 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive. Row 6 · 2022-04-04 · Exercise / conversion · Acquired 6,285 · Balance 41,267 Row 7 · 2022-04-04 · Exercise / conversion · Acquired 9,625 · Balance 50,892 Row 8 · 2022-04-04 · Exercise / conversion · Acquired 16,875 · Balance 67,767 Row 9 · 2022-04-04 · Sale · Disposed 2,500 · Balance 65,267 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive. Row 10 · 2022-04-04 · Sale · Disposed 18,076 · Balance 47,191 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive. Row 11 · 2022-04-04 · Sale · Disposed 3,200 · Balance 43,991 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive. Row 12 · 2022-04-04 · Sale · Disposed 9,009 · Balance 34,982 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2025-11-20 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-04-01 · Exercise / conversion · Disposed 16,000 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2026-11-18 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-04-01 · Exercise / conversion · Disposed 31,664 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.52 · Expires 2027-11-17 | Direct | 6,285 |
Reported balance
After 2022-04-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-04-01 · Exercise / conversion · Disposed 2,895 · Balance 6,285 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.52 · Expires 2027-11-17 | Direct | 0 |
Reported balance
After 2022-04-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-04-04 · Exercise / conversion · Disposed 6,285 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.57 · Expires 2030-11-20 | Direct | 21,175 |
Reported balance
After 2022-04-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-04-04 · Exercise / conversion · Disposed 9,625 · Balance 21,175 F9: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.35 · Expires 2029-11-18 | Direct | 13,125 |
Reported balance
After 2022-04-04 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-04-04 · Exercise / conversion · Disposed 16,875 · Balance 13,125 F10: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
F8: 100% of the shares subject to the option are fully vested and exercisable.
F9: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
F10: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,268 | $113.90 | $144,426.21 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $113.44 to $114.28, inclusive. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000024 · edgar.xml · derivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,090 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,955 | $105.57 | $311,951.08 |
DisclosureSEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $106.00, inclusive. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 800 | $104.81 | $83,844.00 |
DisclosureSEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.47 to $104.95, inclusive. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 400 | $103.85 | $41,538.04 |
DisclosureSEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,555 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $103.64 to $103.96, inclusive. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000024 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000022 · edgar.xml · derivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,045 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,425 | $85.92 | $208,354.30 |
DisclosureSEC source: 0001177648-18-000022 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.47 to $86.45, inclusive. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,800 | $85.11 | $153,205.38 |
DisclosureSEC source: 0001177648-18-000022 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,425 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.45, inclusive. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000022 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 2,566 | $76.85 | $197,184.27 |
DisclosureSEC source: 0001177648-18-000007 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,270 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 6,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-18-000007 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,836 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:28 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-18-000007 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,808 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018. Read SEC document |
| November 17, 2017 Filed Nov 22, 2017 00:57 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001177648-17-000039 · edgar.xml · derivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2027-11-17 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017). Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:40 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 792 | $29.82 | $23,613.48 |
DisclosureSEC source: 0001177648-17-000004 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 F2 · shares: Represents the number of shares of common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU award. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:40 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-17-000004 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 F1 · shares: Represents shares of common stock issued upon vesting of a performance share unit ("PSU") award granted on February 20, 2015 as a result of the achievement of a clinical development milestone in 2016 and the settlement and issuance of those shares of common stock on Febuary 13, 2017. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:04 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-16-000029 · edgar.xml · derivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into shares of common stock on a one-for-one basis. F3 · derivative.exercise_date: Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. F3 · derivative.expiration_date: Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. Read SEC document |
| November 18, 2016 Filed Nov 23, 2016 00:04 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001177648-16-000029 · edgar.xml · derivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2026-11-18 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2016). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.